Replication and Pathogenesis of Hepatitis C Virus

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 125-147

  Moradpour, Darius ^a   Rice, Charles M ^b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Laboratory of Virology and Infectious Disease   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882899491     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50013-9     Document Type: Chapter

References (286)

1. Management of Hepatitis C: 2002. Hepatology 2002, 36:S2-S20. National Institutes of Health Consensus Development Conference Statement.
2. Manns MP, McHutchison JG, Gordon SC, et al. and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
3. Fried M, Shiffman M, Reddy K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
4. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
5. Muir AJ, Bornstein JD, Killenberg PG Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
6. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
7. Davis GL, Albright JE, Cook SF, Rosenberg DM Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331-338.
8. Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
9. Grakoui A, McCourt DW, Wychowski C, et al. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993, 67:2832-2843.
10. Bartenschlager R, Ahlborn-Laake L, Yasargil K, Mous J, Jacobsen H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 1994, 68:5045-5055.
11. Kolykhalov AA, Agapov EV, Blight KJ, et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997, 277:570-574.
12. Lohmann V, Körner F, Koch J-O, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
13. Blight KJ, Kolykhalov AA, Rice CM Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972-1974.
14. Bartosch B, Dubuisson J, Cosset FL Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003, 197:633-642.
15. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003, 100:7271-7276.
16. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004, 63:71-180.
17. Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
18. Lindenbach BD, Rice CM Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
19. Seeger C. Salient molecular features of hepatitis C virus revealed. Trends Microbiol 2005, 13:528-534.
20. van Regenmortel MHV, Fauquet CM, Bishop DHL, et al. Virus taxonomy. The VIIth Report of the International Committee on Taxonomy of Viruses 2000, Academic Press, San Diego.
21. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004, 85:3173-3188.
22. Yanagi M, Purcell RH, Emerson SU, Bukh J Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 1997, 94:8738-8743.
23. Hong Z, Beaudet-Miller M, Lanford RE, et al. Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees. Virology 1999, 256:36-44.
24. Lanford RE, Lee H, Chavez D, et al. Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence. J Gen Virol 2001, 82:1291-1297.
25. Beard MR, Abell G, Honda M, et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology 1999, 30:316-324.
26. Yanagi M, Purcell RH, Emerson SU, Bukh J Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 1999, 262:250-263.
27. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 2000, 74:2046-2051.
28. Sakai A, Claire MS, Faulk K, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 2003, 100:11646-11651.
29. Rijnbrand RC, Lemon SM Internal ribosome entry site-mediated translation in hepatitis C virus replication. Curr Topics Microbiol Immunol 2000, 242:85-116.
30. Sarnow P. Viral internal ribosome entry site elements: novel ribosome-RNA complexes and roles in viral pathogenesis. J Virol 2003, 77:2801-2806.
31. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001, 75:12047-12057.
32. Spahn CM, Kieft JS, Grassucci RA, et al. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40S ribosomal subunit. Science 2001, 291:1959-1962.
33. Lukavsky PJ, Otto GA, Lancaster AM, et al. Structures of two RNA domains essential for hepatitis C virus internal ribosome entry site function. Nature Struct Biol 2000, 7:1105-1110.
34. Collier AJ, Gallego J, Klinck R, et al. A conserved RNA structure within the HCV IRES eIF3-binding site. Nature Struct Biol 2002, 9:375-380.
35. Kieft JS, Zhou K, Grech A, et al. Crystal structure of an RNA tertiary domain essential to HCV IRES-mediated translation initiation. Nature Struct Biol 2002, 9:370-374.
36. Lukavsky PJ, Kim I, Otto GA, Puglisi JD Structure of HCV IRES domain II determined by NMR. Nature Struct Biol 2003, 10:1033-1038.
37. Otto GA, Puglisi JD The pathway of HCV IRES-mediated translation initiation. Cell 2004, 119:369-380.
38. Kolykhalov AA, Feinstone SM, Rice CM Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA. J Virol 1996, 70:3363-3371.
39. Tanaka T, Kato N, Cho M-J, et al. Structure of the 3′ terminus of the hepatitis C virus genome. J Virol 1996, 70:3307-3312.
40. Yanagi M, St Claire M, Emerson SU, et al. In vivo analysis of the 3′ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA 1999, 96:2291-2295.
41. Friebe P, Bartenschlager R. Genetic analysis of sequences in the 3′ nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 2002, 76:5326-5338.
42. Yi M, Lemon SM 3′ nontranslated RNA signals required for replication of hepatitis C virus RNA. J Virol 2003, 77:3557-3568.
43. Yi M, Lemon SM Structure-function analysis of the 3′ stem-loop of hepatitis C virus genomic RNA and its role in viral RNA replication. RNA 2003, 9:331-345.
44. Kim YK, Kim CS, Lee SH, Jang SK Domains I and II in the 5′ nontranslated region of the HCV genome are required for RNA replication. Biochem Biophys Res Commun 2002, 290:105-112.
45. Smith DB, Simmonds P Characteristics of nucleotide substitution in the hepatitis C virus genome: constraints on sequence change in coding regions at both ends of the genome. J Mol Evol 1997, 45:238-246.
46. Walewski JL, Keller TR, Stump DD, Branch AD Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001, 7:710-721.
47. You S, Stump DD, Branch AD, Rice CM A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 2004, 78:1352-1366.
48. Friebe P, Boudet J, Simorre J-P, Bartenschlager R A kissing loop interaction in the 3′ end of the hepatitis C virus genome essential for RNA replication. J Virol 2005, 79:380-392.
49. Pietschmann T, Lohmann V, Rutter G, et al. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001, 75:1252-1264.
50. McLauchlan J, Lemberg MK, Hope G, Martoglio B Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002, 21:3980-3988.
51. Moradpour D, Englert C, Wakita T, Wands JR Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996, 222:51-63.
52. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997, 94:1200-1205.
53. Egger D, Wölk B, Gosert R, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002, 76:5974-5984.
54. Hope RG, Murphy DJ, McLauchlan J The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. J Biol Chem 2002, 277:4261-4270.
55. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Med 1998, 4:1065-1067.
56. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122:352-365.
57. Kunkel M, Lorinczi M, Rijnbrand R, et al. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol 2001, 75:2119-2129.
58. Klein KC, Polyak SJ, Lingappa JR Unique features of hepatitis C virus capsid formation revealed by de novo cell-free assembly. J Virol 2004, 78:9257-9269.
59. McLauchlan J. Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. J Viral Hepat 2000, 7:2-14.
60. Tellinghuisen TL, Rice CM Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol 2002, 5:419-427.
61. Xu Z, Choi J, Yen TS, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 2001, 20:3840-3848.
62. Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P. Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 2002, 277:17713-17721.
63. Choi J, Xu Z, Ou JH Triple decoding of hepatitis C virus RNA by programmed translational frameshifting. Mol Cell Biol 2003, 23:1489-1497.
64. Boulant S, Becchi M, Penin F, Lavergne JP Unusual multiple recoding events leading to alternative forms of hepatitis C virus core protein from genotype 1b. J Biol Chem 2003, 278:45785-45792.
65. Komurian-Pradel F, Rajoharison A, Berland JL, et al. Antigenic relevance of F protein in chronic hepatitis C virus infection. Hepatology 2004, 40:900-909.
66. Bain C, Parroche P, Lavergne JP, et al. Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection. J Virol 2004, 78:10460-10469.
67. McMullan LK, Grakoui A, Puig M, et al. Evidence for a functional RNA element in the hepatitis C virus alternative reading frame. In preparation.
68. Branch AD, Stump DD, Gutierrez JA, et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis 2005, 25:105-117.
69. Op De Beeck A, Cocquerel L, Dubuisson J Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol 2001, 82:2589-2595.
70. Cocquerel L, Op de Beeck A, Lambot M, et al. Topologic changes in the transmembrane domains of hepatitis C virus envelope glycoproteins. EMBO J 2002, 21:2893-2902.
71. Rey FA, Heinz FX, Mandl C, et al. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 1995, 375:291-298.
72. Yagnik AT, Lahm A, Meola A, et al. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 2000, 40:355-366.
73. Lescar J, Roussel A, Wien MW, et al. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 2001, 105:137-148.
74. Modis Y, Ogata S, Clements D, Harrison SC A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003, 100:6986-6991.
75. Hijikata M, Kato N, Ootsuyama Y, et al. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991, 175:220-228.
76. Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991, 180:842-848.
77. Penin F, Combet C, Germanidis G, et al. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 2001, 75:5703-5710.
78. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996, 93:15394-15399.
79. Forns X, Thimme R, Govindarajan S, et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 2000, 97:13318-13323.
80. Carrère-Kremer S, Montpellier-Pala C, Cocquerel L, et al. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 2002, 76:3720-3730.
81. Harada T, Tautz N, Thiel HJ E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studies. J Virol 2000, 74:9498-9506.
82. Griffin SD, Beales LP, Clarke DS, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug amantadine. FEBS Lett 2003, 535:34-38.
83. Pavlovic D, Neville DC, Argaud O, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci USA 2003, 100:6104-6108.
84. Ferlenghi I, Clarke M, Ruttan T, et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell 2001, 7:593-602.
85. Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002, 108:717-725.
86. Mukhopadhyay S, Kim BS, Chipman PR, et al. Structure of West Nile virus. Science 2003, 302:248.
87. Feinstone SM, Mihalik KB, Kamimura T, et al. Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect Immun 1983, 41:816-821.
88. He LF, Alling D, Popkin T, et al. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 1987, 156:636-640.
89. Kaito M, Watanabe S, Tsukiyama-Kohara K, et al. Hepatitis C virus particle detected by immunoelectron microscopy study. J Gen Virol 1994, 75:1755-1760.
90. Shimizu YK, Feinstone SM, Kohara M, et al. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology 1996, 23:205-209.
91. André P, Komurian-Pradel F, Deforges S, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002, 76:6919-6928.
92. Maillard P, Krawczynski K, Nitkiewicz J, et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol 2001, 75:8240-8250.
93. Grakoui A, McCourt DW, Wychowski C, et al. A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci USA 1993, 90:10583-10587.
94. Hijikata M, Mizushima H, Akagi T, et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 1993, 67:4665-4675.
95. Waxman L, Whitney M, Pollok BA, et al. Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci USA 2001, 98:13931-13935.
96. Santolini E, Pacini L, Fipaldini C, et al. The NS2 protein of hepatitis C virus is a transmembrane polypeptide. J Virol 1995, 69:7461-7471.
97. Yamaga AK, Ou JH Membrane topology of the hepatitis C virus NS2 protein. J Biol Chem 2002, 277:33228-33234.
98. Pallaoro M, Lahm A, Biasiol G, et al. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J Virol 2001, 75:9939-9946.
99. Thibeault D, Maurice R, Pilote L, et al. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J Biol Chem 2001, 276:46678-46684.
100. Lorenz I, Marcotrigiano J, Rice CM. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. In preparation.
101. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993, 67:3835-3844.
102. Tomei L, Failla C, Santolini E, et al. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993, 67:4017-4026.
103. De Francesco R, Steinkühler C. Structure and function of the hepatitis C virus NS3-NS4A serine protease. Curr Topics Microbiol Immunol 2000, 242:149-169.
104. Kwong AD, Kim JL, Lin C Structure and function of hepatitis C virus NS3 helicase. Curr Topics Microbiol Immunol 2000, 242:171-196.
105. Wölk B, Sansonno D, Kräusslich H-G, et al. Subcellular localization, stability and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 2000, 74:2293-2304.
106. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996, 87:343-355.
107. Love RA, Parge HE, Wickersham JA, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996, 87:331-342.
108. Yan Y, Li Y, Munshi S, et al. Complex of NS3 protease and NS4A peptide of BK strain of hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Sci 1998, 7:837-847.
109. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nature Struct Biol 1997, 4:463-467.
110. Kim JL, Morgenstern KA, Griffith JP, et al. Hepatitis virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure Fold Des 1998, 6:89-100.
111. Yao N, Reichert P, Taremi SS, et al. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure Fold Des 1999, 7:1353-1363.
112. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
113. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127:1347-1355.
114. Serebrov V, Pyle AM Periodic cycles of RNA unwinding and pausing by hepatitis C virus NS3 helicase. Nature 2004, 430:476-480.
115. Hügle T, Fehrmann F, Bieck E, et al. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 2001, 284:70-81.
116. Qu L, McMullan LK, Rice CM Isolation and characterization of noncytopathic pestivirus mutants reveals a role for nonstructural protein NS4B in viral cytopathogenicity. J Virol 2001, 75:10651-10662.
117. Lundin M, Monne M, Widell A, et al. Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol 2003, 77:5428-5438.
118. Gosert R, Egger D, Lohmann V, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003, 77:5487-5492.
119. Reed KE, Gorbalenya AE, Rice CM The NS5A/NS5 proteins of viruses from three genera of the family flaviviridae are phosphorylated by associated serine/threonine kinases. J Virol 1998, 72:6199-6206.
120. Katze MG, Kwieciszewski B, Goodlett DR, et al. Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A. Virology 2000, 278:501-513.
121. Reed K, Rice CM Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. J Biol Chem 1999, 274:28011-28018.
122. Koch JO, Bartenschlager R Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol 1999, 73:7138-7146.
123. Neddermann P, Clementi A, De Francesco R. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein. J Virol 1999, 73:9984-9991.
124. Brass V, Bieck E, Montserret R, et al. An aminoterminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 2002, 277:8130-8139.
125. Elazar M, Cheong KH, Liu P, et al. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol 2003, 77:6055-6061.
126. Penin F, Brass V, Appel N, et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004, 279:40835-40843.
127. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 2004, 279:48576-48587.
128. Tellinghuisen TL, Marcotrigiano J, Rice CM Structure of the zinc-binding domain of an essential replicase component of hepatitis C virus reveals a novel fold. Nature 2005, 435:375-379.
129. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996, 334:77-81.
130. Witherell GW, Beineke P Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 2001, 63:8-16.
131. Gale M, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997, 230:217-227.
132. Gale M, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998, 18:5208-5218.
133. Tan S-L, Katze MG How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 2001, 284:1-12.
134. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004, 85:2485-2502.
135. Behrens S-E, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996, 15:12-22.
136. Lohmann V, Körner F, Herian U, Bartenschlager R Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997, 71:8416-8428.
137. Yamashita T, Kaneko S, Shirota Y, et al. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J Biol Chem 1998, 273:15479-15486.
138. Ferrari E, Wright-Minogue J, Fang JW, et al. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J Virol 1999, 73:1649-1654.
139. Ago H, Adachi T, Yoshida A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold Des 1999, 7:1417-1426.
140. Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 1999, 96:13034-13039.
141. Lesburg CA, Cable MB, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct Biol 1999, 6:937-943.
142. Bressanelli S, Tomei L, Rey FA, De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 2002, 76:3482-3492.
143. Butcher SJ, Grimes JM, Makeyev EV, et al. A mechanism for initiating RNA-dependent RNA polymerization. Nature 2001, 410:235-240.
144. Choi KH, Groarke JM, Young DC, et al. The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation. Proc Natl Acad Sci USA 2004, 101:4425-4430.
145. Pata JD, Schultz SC, Kirkegaard K Functional oligomerization of poliovirus RNA-dependent RNA polymerase. RNA 1995, 1:466-477.
146. Hobson SD, Rosenblum ES, Richards OC, et al. Oligomeric structures of poliovirus polymerase are important for function. EMBO J 2001, 20:1153-1163.
147. Lyle JM, Bullitt E, Bienz K, Kirkegaard K Visualization and functional analysis of RNA-dependent RNA polymerase lattices. Science 2002, 296:2218-2222.
148. Qin W, Luo H, Nomura T, et al. Oligomeric interaction of hepatitis C virus NS5B is critical for catalytic activity of RNA-dependent RNA polymerase. J Biol Chem 2002, 277:2132-2137.
149. Wang QM, Hockman MA, Staschke K, et al. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J Virol 2002, 76:3865-3872.
150. Schmidt-Mende J, Bieck E, Hügle T, et al. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2001, 276:44052-44063.
151. Ivashkina N, Wölk B, Lohmann V, et al. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J Virol 2002, 76:13088-13093.
152. Moradpour D, Brass V, Bieck E, et al. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J Virol 2004, 78:13278-13284.
153. Lanford RE, Bigger C Advances in model systems for hepatitis C virus research. Virology 2002, 293:1-9.
154. Shimizu YK, Igarashi H, Kiyohara T, et al. Hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996, 223:409-412.
155. Castet V, Fournier C, Soulier A, et al. Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 2002, 76:8189-8199.
156. Moradpour D, Heim MH, Cerny A, et al. Cell lines that allow regulated expression of HCV proteins: principles and applications. Frontiers in viral hepatitis 2003, 175-186. Elsevier Science, Amsterdam. R.F. Schinazi, J.-P. Sommadossi, C.M. Rice (Eds.).
157. Zhao WD, Wimmer E, Lahser FC Poliovirus/hepatitis C virus (internal ribosomal entry site-core) chimeric viruses: improved growth properties through modification of proteolytic cleavage site and requirement for core RNA sequences but not for core-related polypeptides. J Virol 1999, 73:1546-1554.
158. Filocamo G, Pacini L, Nardi C, et al. Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric Sindbis viruses. J Virol 1999, 73:561-575.
159. Lohmann V, Körner F, Dobierzewska A, Bartenschlager R Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001, 75:1437-1449.
160. Lohmann V, Hoffmann S, Herian U, et al. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003, 77:3007-3019.
161. Evans MJ, Rice CM, Goff SP Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci USA 2004, 101:13038-13043.
162. Neddermann P, Quintavalle M, Di Pietro C, et al. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol 2004, 78:13306-13314.
163. Appel N, Pietschmann T, Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol 2005, 79:3187-3194.
164. Bukh J, Pietschmann T, Lohmann V, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci USA 2002, 99:14416-14421.
165. Frese M, Pietschmann T, Moradpour D, et al. Interferonα inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 2001, 82:723-733.
166. Frese M, Schwärzle V, Barth K, et al. Interferonγ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-703.
167. Foy E, Li K, Wag C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300:1145-1148.
168. Foy E, Li K, Sumpter R, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 2005, 102:2986-2991.
169. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005, 102:2992-2997.
170. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-1 antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
171. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003, 77:3181-3190.
172. Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003, 125:1808-1817.
173. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001, 75:4614-4624.
174. Yi M, Bodola F, Lemon SM Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 2002, 304:197-210.
175. Murray EM, Grobler JA, Markel EJ, et al. Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol 2003, 77:2928-2935.
176. Blight KJ, McKeating JA, Rice CM Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 2002, 76:13001-13014.
177. Ikeda M, Yi M, Li K, Lemon SM Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002, 76:2997-3006.
178. Pietschmann T, Lohmann V, Kaul A, et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002, 76:4008-4021.
179. Zhu Q, Guo JT, Seeger C Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003, 77:9204-9210.
180. Kato T, Date T, Miyamoto M, et al. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 2005, 79:592-596.
181. Moradpour D, Evans MJ, Gosert R, et al. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 2004, 78:7400-7409.
182. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11:791-796.
183. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005, 102:9294-9299.
184. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
185. Xie ZC, Riezu-Boj JI, Lasarte JJ, et al. Transmission of hepatitis C virus infection to tree shrews. Virology 1998, 244:513-520.
186. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004, 39:1469-1475.
187. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999, 10:439-449.
188. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659-662.
189. Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003, 197:1645-1655.
190. Houghton M. Strategies and prospects for vaccination against the hepatitis C viruses. Curr Topics Microbiol Immunol 2000, 242:327-339.
191. Forns X, Bukh J, Purcell RH The challenge of developing a vaccine against hepatitis C virus. J Hepatol 2002, 37:684-695.
192. Inchauspé G, Feinstone S Development of a hepatitis C virus vaccine. Clin Liver Dis 2003, 7:243-259. xi.
193. Beames B, Chavez D, Guerra B, et al. Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus. J Virol 2000, 74:11764-11772.
194. Bukh J, Apgar CL, Yanagi M Toward a surrogate model for hepatitis C virus: an infectious molecular clone of the GB virus-B hepatitis agent. Virology 1999, 262:470-478.
195. De Tomassi A, Pizzuti M, Graziani R, et al. Cell clones selected from the Huh7 human hepatoma cell line support efficient replication of a subgenomic GB virus B replicon. J Virol 2002, 76:7736-7746.
196. Martin A, Bodola F, Sangar DV, et al. Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA. Proc Natl Acad Sci USA 2003, 100:9962-9967.
197. Bright H, Carroll AR, Watts PA, Fenton RJ Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors. J Virol 2004, 78:2062-2071.
198. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nature Med 2001, 7:927-933.
199. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
200. Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999, 96:12766-12771.
201. Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002, 21:5017-5025.
202. Bartosch B, Vitelli A, Granier C, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 2003, 278:41624-41630.
203. Cormier EG, Tsamis F, Kajumo F, et al. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA 2004, 101:7270-7274.
204. Zhang J, Randall G, Higginbottom A, et al. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 2004, 78:1448-1455.
205. Gardner JP, Durso RJ, Arrigale RR, et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003, 100:4498-4503.
206. Pöhlmann S, Zhang J, Baribaud F, et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003, 77:4070-4080.
207. Cormier EG, Durso RJ, Tsamis F, et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci USA 2004, 101:14067-14072.
208. Lozach PY, Amara A, Bartosch B, et al. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 2004, 279:32035-32045.
209. Flint M, Thomas JM, Maidens CM, et al. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 1999, 73:6782-6790.
210. Lozach PY, Lortat-Jacob H, De Lacroix De Lavalette A, et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 2003, 278:20358-20366.
211. Lambot M, Fretier S, Op De Beeck A, et al. Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment. J Biol Chem 2002, 277:20625-20630.
212. Triyatni M, Saunier B, Maruvada P, et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 2002, 76:9335-9344.
213. Wellnitz S, Klumpp B, Barth H, et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 2002, 76:1181-1193.
214. Blanchard E, Brand D, Trassard S, et al. Hepatitis C virus-like particle morphogenesis. J Virol 2002, 76:4073-4079.
215. Lagging LM, Meyer K, Owens RJ, Ray R Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol 1998, 72:3539-3546.
216. Matsuura Y, Tani H, Suzuki K, et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 2001, 286:263-275.
217. Buonocore L, Blight KJ, Rice CM, Rose JK Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 2002, 76:6865-6872.
218. Bressanelli S, Stiasny K, Alison SL, et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 2004, 23:728-738.
219. Gibbons DL, Vaney MC, Roussel A, et al. Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature 2004, 427:320-325.
220. Modis Y, Ogata S, Clements D, Harrison SC Structure of the dengue virus envelope protein after membrane fusion. Nature 2004, 427:313-319.
221. Egger D, Gosert R, Bienz K. Role of cellular structures in viral RNA replication. Molecular biology of picornaviruses 2002, 247-253. ASM Press, Washington DC. B. Semler, E. Wimmer (Eds.).
222. Ahlquist P, Noueiry AO, Lee WM, et al. Host factors in positive-strand RNA virus genome replication. J Virol 2003, 77:8181-8186.
223. Restrepo-Hartwig MA, Ahlquist P. Brome mosaic virus helicase-and polymerase-like proteins colocalize on the endoplasmic reticulum at sites of viral RNA synthesis. J Virol 1996, 70:8908-8916.
224. Schaad MC, Jensen PE, Carrington JC Formation of plant RNA virus replication complexes on membranes: role of an endoplasmic reticulum-targeted viral protein. EMBO J 1997, 16:4049-4059.
225. van der Meer Y, van Tol H, Locker JK, Snijder EJ ORF1a-encoded replicase subunits are involved in the membrane association of the arterivirus replication complex. J Virol 1998, 72:6689-6698.
226. Rust RC, Landmann L, Gosert R, et al. Cellular COPII proteins are involved in production of the vesicles that form the poliovirus replication complex. J Virol 2001, 75:9808-9818.
227. Ritzenthaler C, Laporte C, Gaire F, et al. Grapevine fanleaf virus replication occurs on endoplasmic reticulum-derived membranes. J Virol 2002, 76:8808-8819.
228. Mackenzie JM, Jones MK, Westaway EG Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. J Virol 1999, 73:9555-9567.
229. Gazina EV, Mackenzie JM, Gorrell RJ, Anderson DA Differential requirements for COPI coats in formation of replication complexes among three genera of Picornaviridae. J Virol 2002, 76:11113-11122.
230. Krogerus C, Egger D, Samuilova O, et al. The replication complex of human parechovirus 1. J Virol 2003, 77:8512-8523.
231. Miller DJ, Schwartz MD, Ahlquist P Flock house virus RNA replicates on outer mitochondrial membranes in Drosophila cells. J Virol 2001, 75:11664-11676.
232. Kujala P, Ikäheimonen A, Ehsani N, et al. Biogenesis of the Semliki Forest virus RNA replication complex. J Virol 2001, 75:3873-3884.
233. Schwartz M, Chen J, Janda M, et al. A positive-strand RNA virus replication complex parallels form and function of retrovirus capsids. Mol Cell 2002, 9:505-514.
234. Wu S-X, Ahlquist P, Kaesberg P Active complete in vitro replication of nodavirus RNA requires glycerophospholipid. Proc Natl Acad Sci USA 1992, 89:11136-11140.
235. Ahola T, Lampio A, Auvinen P, Kääriäinen L. Semliki Forest virus mRNA capping enzyme requires association with anionic membrane phospholipids for activity. EMBO J 1999, 18:3164-3172.
236. Shirota Y, Luo H, Qin W, et al. Hepatitis C virus NS5A binds RNA-dependent RNA polymerase NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002, 277:11149-11155.
237. Dimitrova M, Imbert I, Kieny MP, Schuster C Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol 2003, 77:5401-5414.
238. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol 2002, 12:517-523.
239. Moradpour D, Gosert R, Egger D, et al. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res 2003, 60:103-109.
240. Ye J, Wang C, Sumpter R, et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003, 100:15865-15870.
241. Kapadia SB, Chisari FV Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005, 102:2561-2566.
242. Brass V, Blum HE, Moradpour D Recent developments in target identification against hepatitis C virus. Expert Opin Ther Targets 2004, 8:295-307.
243. Pawlotsky JM, McHutchison JG, Hepatitis C Development of new drugs and clinical trials: promises and pitfalls. Hepatology 2004, 39:554-567.
244. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436:953-960.
245. Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003, 77:3669-3679.
246. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005, 41:832-835.
247. Choo Q-L, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994, 91:1294-1298.
248. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258:135-140.
249. Prince AM, Brotman B, Huima T, et al. Immunity in hepatitis C infection. J Infect Dis 1992, 165:438-443.
250. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994, 343:388-390.
251. Bassett SE, Guerra B, Brasky K, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001, 33:1479-1487.
252. Major ME, Mihalik K, Puig M, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002, 76:6586-6595.
253. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-1483.
254. Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003, 38:1290-1296.
255. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
256. Cerny A, Chisari FV Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999, 30:595-601.
257. Shoukry NH, Cawthon AG, Walker CM Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004, 58:391-424.
258. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev Immunol 2005, 5:215-229.
259. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T lymphocyte response to non structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995, 346:1006-1007.
260. Missale G, Bertoni R, Lamonaca V, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996, 98:706-714.
261. Cerny A, McHutchinson JG, Pasquinelli C, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995, 95:521-530.
262. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 191:1499-1512.
263. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001, 194:1395-1406.
264. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002, 99:15661-15668.
265. Major ME, Dahari H, Mihalik K, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004, 39:1709-1720.
266. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002, 99:15669-15674.
267. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Med 2002, 8:379-385.
268. Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004, 78:5867-5874.
269. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature Med 2000, 6:578-582.
270. Heim MH, Moradpour D, Blum HE Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999, 73:8469-8475.
271. Blindenbacher A, Duong FH, Hunziker L, et al. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003, 124:1465-1475.
272. Duong FH, Filipowicz M, Tripodi M, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004, 126:263-277.
273. Taylor DR, Shi ST, Romano PR, et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285:107-110.
274. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002, 195:35-41.
275. Tseng CT, Klimpel GR Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002, 195:43-49.
276. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305:872-874.
277. Bain C, Fatmi A, Zoulim F, et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001, 120:512-524.
278. Longman RS, Talal AH, Jacobson IM, et al. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004, 103:1026-1029.
279. Shimizu YK, Hijikata M, Iwamoto A, et al. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994, 68:1494-1500.
280. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
281. Chang K-M, Rehermann B, McHutchison JG, et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997, 100:2376-2385.
282. Tsai SL, Chen YM, Chen MH, et al. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 1998, 115:954-965.
283. Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001, 15:883-895.
284. Seifert U, Liermann H, Racanelli V, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004, 114:250-259.
285. Logvinoff C, Major ME, Oldach D, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004, 101:10149-10154.
286. Yu MY, Bartosch B, Zhang P, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 2004, 101:7705-7710.